How do you use Neoantigen in a sentence? See 2 example sentences showing how this word appears in different contexts, plus the exact meaning.
Neoantigen meaning
A newly-acquired antigen
Using Neoantigen
- The main meaning on this page is: A newly-acquired antigen
Context around Neoantigen
- Average sentence length in these examples: 28.5 words
- Position in the sentence: 0 start, 1 middle, 1 end
- Sentence types: 2 statements, 0 questions, 0 exclamations
Corpus analysis for Neoantigen
- In this selection, "neoantigen" usually appears in the middle of the sentence. The average example has 28.5 words, and this corpus slice is mostly made up of statements.
- Around the word, individualised, antigen and therapy stand out and add context to how "neoantigen" is used.
- Recognizable usage signals include an individualised neoantigen therapy int and new antigen neoantigen can be. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "neoantigen" sits close to words such as aabc, aacr and aacsb, which helps place it inside the broader word index.
Example types with neoantigen
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
However, predicting whether a patient will have an immune response to a particular abnormal protein caused by mutations that serves as a new antigen (neoantigen), can be challenging. (28 words)
The new jab, which is set to be tested on around 1,100 patients worldwide, is an individualised neoantigen therapy (INT) and sometimes referred to as a cancer vaccine. (29 words)
The new jab, which is set to be tested on around 1,100 patients worldwide, is an individualised neoantigen therapy (INT) and sometimes referred to as a cancer vaccine. (29 words)
However, predicting whether a patient will have an immune response to a particular abnormal protein caused by mutations that serves as a new antigen (neoantigen), can be challenging. (28 words)
Example sentences (2)
The new jab, which is set to be tested on around 1,100 patients worldwide, is an individualised neoantigen therapy (INT) and sometimes referred to as a cancer vaccine.
However, predicting whether a patient will have an immune response to a particular abnormal protein caused by mutations that serves as a new antigen (neoantigen), can be challenging.